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increase, the situation of cases with Boutonneuse fever dur-
ing last 15 years were:
Year - (No. of cases) 1991 - (3); 1992 - (6); 1993 - (12);
1994 - (26); 1995 - (24); 1996 - (27); 1997 - (21); 1998 - (30);
1999 - (68); 2000 - (13); 2001 - (30); 2002 - (17); 2003 - (14);
2004 - (16); 2005 - (99); 2006 - (61); 2007 - (25)
Conclusions: The monthly distribution of this disease
reﬂects seasonality of this affection, according with max-
imum period of thick spreading and human contact with
them. The year 2001 as 2000 register in June, especially
July and August the pick of morbidity, according to period of
maximum spread of ticks and human contacts with them and
for these years temperatures over the multiannual average.
doi:10.1016/j.ijid.2008.05.378
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tion (AEFI) with Human Papillomavirus (HPV) Vaccine in
Canada (Sep. 2006 — Dec. 2007)
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Background: The Quadrivalent HP Recombinant Vaccine,
GardasilTM was approved in Canada in July 2006 and has been
in use since September 2006. Gardasil is offered to females
between 9 and 26 years of age. The aim of this vaccine is
to prevent the diseases associated with HPV types 6, 11,
16, 18 (cervical cancer and anogenital warts). Some juris-
dictions have already included this vaccine in their school
based immunization program.
Methods: All Adverse Event Following Immunization
reports received by the Public Health Agency of Canada
through passive and active surveillance programs were
reviewed and included in the analysis.
Results: A total of 148 reports of AEFI was received by the
Agency between September 2006 and December 2007, with a
reporting rate estimated at 38/100,000 doses distributed. In
majority of cases (97.4%) HPV vaccine was the only vaccine
given.
The age ranged from 10 to 45 years old with median at
18.0 and StD 5.8 years.
The most commonly reported AEFIs were injection site
pain (20%), other injection site reactions (8%), nausea
(8%); dizziness, headache, rash and vomiting (each 7.5%),
urticaria (7%); and diarrhea, fever, rash and syncope (each
6%). There were two reports of serious AEFIs - one anaphy-
lactic reaction and one encephalopathy.
Medical attention was sought by 51 cases (35%), including
4 hospitalizations, 10 emergency room visits and 37 outpa-
tient visits. The outcome was reported in 58 reports (40%),
of which 41 reported full recovery, 10 recovering, and 7
reported some residual effect at the time of reporting.
Conclusion: Gardasil is considered a safe vaccine in
Canada. AEFIs reported following this vaccine were mainly
minor injection site reactions and mild systemic events.
AEFI data collected through the Canadian active and pas-
sive surveillance programs have been consistent with the
data obtained from the pre-licensure clinical trials.
doi:10.1016/j.ijid.2008.05.379
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Background: Safety and reactogenicity of the candidate
10-valent Pneumococcal non-typeable Haemophilus inﬂuen-
zae Protein D-conjugate vaccine (PHiD-CV, GlaxoSmithKline
Biologicals), designed to protect infants against pneumo-
coccal and non-typeable Haemophilus inﬂuenzae diseases,
were evaluated when co-administered with DTPw-HBV/Hib
and OPV vaccines at 6—10—14 weeks of age (EPI schedule)
in the Philippines.
Methods: In this double-blind, controlled study
(107007/NCT00344318), 400 healthy Filipino infants 6
to 12 weeks old were randomized (3:1) to receive either
PHiD-CV or licensed 7vCRM vaccine (PrevenarTM/PrevnarTM),
both co-administered with DTPw-HBV/Hib +OPV. Solicited
local (pain, redness, swelling), general (fever, drowsiness,
irritability, loss of appetite) and unsolicited symptoms as
well as serious adverse events (SAEs) were recorded after
each vaccination. Intensity was assessed on a scale from
1—3.
Results: The most frequently reported solicited local
grade 3 symptoms were pain following 9.4% of vaccine
doses in both groups and swelling following 9.3% (PHiD-
CV) and 8.1% (7vCRM) vaccine doses. Irritability was the
most frequently reported solicited general grade 3 symptom
following 2.9% (PHiD-CV) and 2.4% (7vCRM) vaccine doses.
Observed overall/dose incidence of fever (rectal temper-
ature ≥38 ◦C) was within the same range in both groups
(PHiD-CV: 60.9%; 7vCRM: 63.0%) with no cases of rectal fever
>40 ◦C. Seven infants reported at least one SAE: 6 in the
PHiD-CV group and 1 in the 7vCRM group. None of them
was assessed by the investigator to be causally related to
vaccination and all resolved without sequelae.
Conclusion: No clinically relevant differences were
observed between the safety and reactogenicity proﬁles of
PHiD-CV and 7vCRM vaccines.
doi:10.1016/j.ijid.2008.05.380
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Background: Measles has been universally known as a
major child health problem and a killer of children mainly
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affecting the young children below 5 years of age in devel-
oping countries like India.
Measles morbidity and mortality has shown a declin-
ing trend in India because of increasing vaccine coverage.
Measles coverage level for India is 90% and for Delhi the
coverage level is 85%. In India there is paucity of data for
measles.
Thus, the present study was proposed with the following
objectives:
• To estimate the incidence of measles among under ﬁve
children of slum of Madipur.
• To estimate the vaccination coverage for measles in under
ﬁve children of slum of Madipur.
Material and Methods: A cross - sectional study was done
in the slum of Madipur, West Delhi, India on all children from
0-59 months of age of the slum area. The slum is divided in
to 6 blocks A, B, C, D, E and F.
Total 781 children were included ie. 130 children from
each block and their parents were interviewed through pre-
formed, pretested, structured questionnaire.
Operational Deﬁnition for Suspect Measles Case: Any
child with fever and maculopapular rash (i.e. non-vesicular)
and cough, coryza (i.e. runny nose) or conjunctivitis (i.e.
red eyes).
Results: Measles vaccination coverage in slum was 77.8%.
79.6% male children and 75.5% female children were immu-
nized. The annual incidence of measles was 6.1%. Amongst
measles cases only 3.1% were immunized and 16.7% were
unimmunized The commonest reason for non vaccination
was unawareness of the need (48%) for vaccination.56.25%
0f measles cases were treated outside the house most com-
monly by a private practitioner. 47.9% children with measles
developed complications due to measles.
Conclusions: The immunization status was much below
the national target of 90% and Delhi target of 85%.immu-
nization status was better in males than in females. The
incidence of measles was high. Measles occurred more in
unimmunized than in immunized. Lack of awareness for
measles vaccination was also observed.
doi:10.1016/j.ijid.2008.05.381
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Background: Clearance of hepatitis B infection is asso-
ciated with T-cell responses to hepatitis B core antigen
(HBcAg). Emergent has developed an attenuated Salmonella
typhi vector (spi-VECTM) carrying an HBcAg gene under the
control of an in vivo regulated promoter (M04NM11).
Methods: 30 healthy subjects aged 18-50 years received
two doses of M04NM11 at a 56 day interval (10
subjects108 cfu, 20 subjects 109 cfu). Peripheral blood
mononuclear cells were collected before treatment and 14
and 28 days after each immunisation for HBcAg assays.
PBMCs were incubated with puriﬁed recombinant HBcAg
(rHBcAg) or one of four peptide pools each containing 4 or
5 sequential synthetic 20-25 residue peptides. Supernatants
were assayed for interferon gamma and IL-5 by ELISA.
Other assays were performed for:
• T-cell proliferation in response to HBcAg or the peptide
pools
• IgM and total Ig to HBcAg
• IgG to S. typhi LPS
• IgA antibody secreting cells (ASC) to S. typhi LPS
• Stool culture daily till day 7, then 11, 14, 21 and 28 days
after immunisation
• Aerobic blood culture 4, 7, 11, 14 and 28 days after immu-
nisation.
Results: Immunogenicity results are shown in the Table
below.
There were no serious adverse events or withdrawals due
to adverse events.
The vaccine strain was not detected in any blood culture
and there were no stools positive after day 5.
Conclusion: M04NM11 given as two doses at a 56 day
interval at doses of 108 and 109 cfu/dose induced a speciﬁc
interferon gamma T-cell response to HBcAg.
doi:10.1016/j.ijid.2008.05.382
19.037
Improving Age Appropriate Immunization: Experience
from Rural North India
S. Prinja ∗, M. Gupta, A. Singh, R. Kumar
School of Public Health, Postgraduate Institute of Medical
Education and Research, Chandigarh, India
Objectives: To identify operational bottlenecks in the
delivery of immunization program and; to ascertain impact
of the interventions aimed at improving extent of age appro-
priate immunization.
Methods: Study was conducted in community develop-
ment block of a north Indian state from July 2005 to
December 2006. Delivery of immunization program was crit-
ically reviewed by observation of facilities and outreach
sessions, and interview of the caretakers of dropout chil-
dren. An intervention package was evolved with community
volunteers at sub health centre level serving as critical
input along with better program management. All exist-
ing children under 18 month of age and new births during
study period were enrolled and their immunization data was
recorded. Mean age at vaccine administration was computed
for DPT doses and trend of age appropriate immunization
coverage was estimated at 5% signiﬁcance level.
Findings: Staff shortage, non-adherence to micro-
planning, and vaccine stock outs led to delayed immuniza-
